Project Grant HT94252410496

Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...

Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $922,755 to the University of Massachusetts Medical School on August 28, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate tRNA modification reprogramming and translational remodeling in cancer. The five-year project, scheduled for completion on July 31, 2030, will comprehensively examine how chemical modifications of transfer RNA (tRNA) and their...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $596,501 to The University of Texas Southwestern Medical Center on June 20, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds fundamental research investigating the molecular mechanisms of translocation renal cell carcinoma (TRCC), a rare and aggressive pediatric kidney cancer subtype characterized by chromosomal translocations of the microphtalmia transcription...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $339,736 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. (DFCI) on May 7, 2025, with completion anticipated by April 30, 2030. This award supports research aimed at resolving diagnostic and phenotypic challenges in translocation renal cell carcinoma (TRCC), a rare and aggressive cancer subtype that is frequently misdiagnosed due to phenotypic overlap with...

Federal Cooperative Agreement Summary The National Cancer Institute awarded a Cooperative Agreement totaling $953,922 to Scripps Research Institute, effective September 1, 2025 through August 31, 2030, under the Cancer Biology Research program (CFDA 93.396). This award supports fundamental research investigating the relationships between ribosomal RNA (rRNA) and transfer RNA (tRNA) modifications, codon usage patterns, translation rates, and metabolic processes in cancer cells. The research...

Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a $473,372 Project Grant under the Cancer Biology Research program (CFDA 93.396) to investigate proline tRNA (transfer RNA) biogenesis as an oncogenic driver and therapeutic target in T cell acute lymphoblastic leukemia (T-ALL). The research, which commenced April 8, 2026, and extends through March 31, 2031, will characterize the molecular mechanisms by which upregulated...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded Baylor College of Medicine a $882,470 Research Specialist (Clinician Scientist) Award under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025 through August 31, 2030. This Project Grant supports the expansion of leadership in the design and conduct of NCI-funded clinical trials for children, adolescents, and young adults with cancer, with particular focus on hematologic malignancies. The...

Federal Grant Award Summary The National Cancer Institute awarded $138,846 to the University Health Network under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a two-year Project Grant commencing August 1, 2025 and concluding July 31, 2027. The award supports the development of laboratory-generated "wild-like" mouse models designed to enhance the translational relevance of preclinical cancer and immunotherapy research. The primary deliverable involves adapting...